Ladenburg Thalmann launched coverage of Exicure (OTCQB:XCUR) with a “buy” rating and $18 price target. The stock closed at $5.65 on July 10. Exicure is developing first-in-class spherical nucleic acid (SNA)...

Leerink launched coverage of Krystal Biotech (NASDAQ:KRYS) with a “buy” rating and $29 fair value estimate. The stock closed at $15.07 on July 9. Krystal is developing novel gene therapies for skin diseases, with lead...

Leerink downgraded Regulus Therapeutics (NASDAQ:RGLS) to “market perform” from “outperform” and slashed its price target to 35 cents from $2 after the company announced that both of its lead clinical programs are on...

William Blair launched coverage of Rocket Pharmaceuticals (NASDAQ:RCKT) with an “outperform” rating and fair value estimate of $32. The stock finished at $19.17 on July 9. Rocket is focused on developing first-in-class...

Ladenburg Thalmann initiated coverage of ContraFect (NASDAQ:CFRX) with a “buy” rating and $3 price target. The stock closed at $2.59 on July 9. “We view ContraFect as a biologics story with a potential first-in-class...

Roth Capital Partners launched coverage of Kalvista Pharmaceuticals (NASDAQ:KALV) with a “buy” rating and price target of $20. The stock closed at $8.82 on July 9. Analyst Jotin Marango writes that behind its cultivated...

H.C. Wainwright launched coverage of RXi Pharmaceuticals (NASDAQ:RXII) with a “buy” rating and price target of $3. The stock closed at $1.97 on July 6. RXi is focused on improving the efficiency and anti-tumor activity...

Leerink downgraded Epizyme (NASDAQ:EPZM) to “market perform” from “outperform” and lowered its price target to $16 from $24 after making extensive changes to its revenue forecasts for Epizyme’s only drug, tazemetostat...

Neuronetics (NASDAQ:STIM) priced its initial public offering of 5.5 million shares common shares at $17 each. The company also granted underwriters a 30-day option to purchase up to an additional 825,000 shares at the...

Maxim Group downgraded Keryx Biopharmaceuticals (NASDAQ:KERX) to “hold” from “buy” and removed its price target after Keryx and Akebia Therapeutics (NASDAQ:AKBA) unveiled a definitive agreement to merge in an all-stock...

H.C. Wainwright launched coverage of AquaBounty Technologies (NASDAQ:AQB) with a “buy” rating and a “conservative” $3.75 price target. The stock closed at $2.99 on June 27. AquaBounty is focused on enhancing...

BTIG downgraded TransEnterix (NASDAQ:TRXC) to “neutral” from “buy,” citing a tripling in the stock price, which has exceeded its price target of $3.50. The stock closed at $5.84 on June 27. “We continue to like the...

The common shares of Imagin Medical (CSE:IME; OTC:IMEXF) were approved for uplisting from the Pink Open Market to the OTCQB Venture Market, with the same symbol, IMEXF, effective at the open on June 28, 2018. “Uplisting...

BTIG launched coverage of Zosano Pharma (NASDAQ:ZSAN) with a “buy” rating and 12-month price target of $19. The stock closed at $3.80 on June 27. Zosano is focused on the development of therapeutics using its ADAM...

Ladenburg Thalmann initiated coverage of Palatin Technologies (NYSE MKT:PTN) with a “buy” rating and $3 price target. The stock closed at $1.05 on June 26. Palatin’s lead asset, bremelanotide (BMT), is a melanocortin...

Ladenburg Thalmann launched coverage of Tocagen (NASDAQ: TOCA) with a “buy” rating and $20 price target. The stock closed at $8.81 on June 26. TOCA is developing a novel viral gene therapy for cancer and has developed a...

Analysts for Stifel and Canaccord Genuity raised their price targets for AtriCure (NASDAQ:ATRC) after an analyst day meeting highlighted the significant penetration opportunity in the atrial fibrillation (AF) market...

Maxim Group initiated coverage of IntelGenx (OTCQX:IGXT; TSXV:IGX) with a “buy” rating and price target of $3. The stock closed at 78 cents on June 26. Analyst Jason McCarthy writes that the company’s VersaFilm is a...

H.C. Wainwright initiated coverage of Avenue Therapeutics (NASDAQ:ATXI) with a “buy” rating and price target of $11. The stock closed at $3.77 on June 25. Avenue Therapeutics is focused on the acute care hospital...

H.C. Wainwright launched coverage of Heat Biologics (NASDAQ:HTBX) with a “buy” rating and $6 price target. The stock closed at $2.22 on June 25. The company’s immunotherapy approach for the treatment of tumors is...

Roth Capital Partners initiated coverage of Soleno Therapeutics (NASDAQ:SLNO) with a “buy” rating and $14 price target. The stock closed at $2.32 on June 21. Soleno’s focus is on Prader-Wili Syndrome (PWS), a rare...